Unknown

Dataset Information

0

A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER- cells via endoplasmic reticulum stress-induced apoptosis.


ABSTRACT: Tamoxifen (TAM) is the frontline therapy for estrogen receptor-positive (ER+) breast cancer in premenopausal women that interrupts ER signaling. As tumors with elevated heterogeneity, amounts of ER-negative (ER-) cells are present in ER+ breast cancer that cannot be directly killed by TAM. Despite complete remissions have been achieved in clinical practice, the mechanism underlying the elimination of ER- cells during TAM treatment remains an open issue. Herein, we deciphered the elimination of ER- cells in TAM treatment from the perspective of the bystander effect. Markable reductions were observed in tumorigenesis of ER- breast cancer cells by applying both supernatants from TAM-treated ER+ cells and a transwell co-culture system, validating the presence of a TAM-induced bystander effect. The major antitumor protein derived from ER+ cells, peptidyl-prolyl cis-trans isomerase B (PPIB), is the mediator of the TAM-induced bystander effect identified by quantitative proteomics. The attenuation of ER- cells was attributed to activated BiP/eIF2α/CHOP axis and promoted endoplasmic reticulum stress (ERS)-induced apoptosis, which can also be triggered by PPIB independently. Altogether, our study revealed a novel TAM-induced bystander effect in TAM treatment of ER+ breast cancer, raising the possibility of developing PPIB as a synergistic antitumor agent or even substitute endocrine therapy.

SUBMITTER: Yang T 

PROVIDER: S-EPMC10869711 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

A novel bystander effect in tamoxifen treatment: PPIB derived from ER+ cells attenuates ER- cells via endoplasmic reticulum stress-induced apoptosis.

Yang Tinglin T   Li Wenhui W   Zhou Jun J   Xu Ming M   Huang Ziwei Z   Ming Jie J   Huang Tao T  

Cell death & disease 20240215 2


Tamoxifen (TAM) is the frontline therapy for estrogen receptor-positive (ER+) breast cancer in premenopausal women that interrupts ER signaling. As tumors with elevated heterogeneity, amounts of ER-negative (ER-) cells are present in ER+ breast cancer that cannot be directly killed by TAM. Despite complete remissions have been achieved in clinical practice, the mechanism underlying the elimination of ER- cells during TAM treatment remains an open issue. Herein, we deciphered the elimination of E  ...[more]

Similar Datasets

2024-02-12 | GSE247920 | GEO
2023-11-16 | PXD047000 |
| PRJNA1040911 | ENA
| S-EPMC5239519 | biostudies-literature
| S-EPMC6511168 | biostudies-literature
| S-EPMC11791515 | biostudies-literature
| S-EPMC8197497 | biostudies-literature
| S-EPMC3508929 | biostudies-literature
| S-EPMC10618786 | biostudies-literature
| S-EPMC6063967 | biostudies-literature